Access read The waitlist is a real demand signal, but the question it does not answer is who pays. A device positioned explicitly as the option for families who do not want stimulants lives or dies on reimbursement, and a home-use neuromodulation device for a behavioural indication sits in exactly the category payers are slowest to cover. Watch coverage decisions, not unit sales. The more interesting strategic line is in the pipeline: Breakthrough Device Designation in drug-resistant epilepsy points the same platform at an indication with clearer medical necessity and a far easier reimbursement argument. ADHD builds the install base and the clinical familiarity; epilepsy is where a platform like this actually gets paid.